Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Lung Neoplasms 4Sezary Syndrome 3Mycosis Fungoides 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Melanoma 1Lymphoma, T-Cell 1Gliosarcoma 1Glioma 1Glioblastoma 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Colitis 1Cholangiocarcinoma 1Cervical Adenocarcinoma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × Disulfides × Clear all
NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡